MicroRNA delivery through nanoparticles

Abstract

MicroRNAs (miRNAs) are attracting a growing interest in the scientific community due to their central role in the etiology of major diseases. On the other hand, nanoparticle carriers offer unprecedented opportunities for cell specific controlled delivery of miRNAs for therapeutic purposes. This review critically discusses the use of nanoparticles for the delivery of miRNA-based therapeutics in the treatment of cancer and neurodegenerative disorders and for tissue regeneration. A fresh perspective is presented on the design and characterization of nanocarriers to accelerate translation from basic research to clinical application of miRNA-nanoparticles. Main challenges in the engineering of miRNA-loaded nanoparticles are discussed, and key application examples are highlighted to underline their therapeutic potential for effective and personalized medicine.

Reversing the Hypoxic Adaptive Response in Breast Cancer Cells through Small-Molecule Inhibition of Oncogenic MicroRNA-210
Marc Panosetti, Donatella Vecchio, Chloé Maucort +4
Journal of Medicinal Chemistry5 Oct 2026Peer-reviewedPublisher termsFull text1 citedGeneral biology Medicinal chemistry & drug discoveryHAL
Aptamer-Targeted PLGA Nanoparticles for Biofilm-Directed Intra-articular Antibiotic Delivery in Prosthetic Joint Infection
Z. Eskandari, Y. Fan, K. Fujino +7
bioRxiv23 Oct 2026PreprintAll rights reservedFull textSystems & synthetic biologybioRxiv
Nanotechnology-based strategies for helminth control: drug delivery, green nanoparticles, mechanisms, and translational barriers.
Bijan Esmaeilnejad, Sayyed Jafar Hasani, Awat Samiei +5
Discover nano21 Oct 2026Peer-reviewedCC BY-NC-NDFull textMicrobiologyEurope PMC
Identification of prognostic biomarkers for nasopharyngeal carcinoma through microRNA‑mRNA network analysis combined with screening of immune‑related genes
Lihe He, Xuan Huang, Ping Huang
PLOS One29 Oct 2026Peer-reviewedCC BYFull textMolecular biology & gene regulation Cell biologyPLOSEurope PMCPMC
Hydrogel crosslinking mechanisms influence the release and functional delivery of lipid nanoparticles
A. G. Schreiber, F. Hauswirth, L. Reger +3
bioRxiv13 Aug 2026PreprintCC BYFull textImmunologybioRxiv

Cite

BibTeX RIS

BibTeX

@article{lee2026microrna,
  title = {{MicroRNA delivery through nanoparticles}},
  author = {Sharon Wei Ling Lee and Camilla Paoletti and Marco Campisi and Tatsuya Osaki and Giulia Adriani and Roger D. Kamm and Clara Mattu and Valeria Chiono},
  journal = {Journal of Controlled Release},
  year = {2026},
  month = oct,
  doi = {10.1016/j.jconrel.2019.10.007},
  url = {https://hal.science/hal-05776432v1},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - MicroRNA delivery through nanoparticles
AU  - Sharon Wei Ling Lee
AU  - Camilla Paoletti
AU  - Marco Campisi
AU  - Tatsuya Osaki
AU  - Giulia Adriani
AU  - Roger D. Kamm
AU  - Clara Mattu
AU  - Valeria Chiono
PY  - 2026
DA  - 2026/10/03
JO  - Journal of Controlled Release
DO  - 10.1016/j.jconrel.2019.10.007
UR  - https://hal.science/hal-05776432v1
AB  - MicroRNAs (miRNAs) are attracting a growing interest in the scientific community due to their central role in the etiology of major diseases. On the other hand, nanoparticle carriers offer unprecedented opportunities for cell specific controlled delivery of miRNAs for therapeutic purposes. This review critically discusses the use of nanoparticles for the delivery of miRNA-based therapeutics in the treatment of cancer and neurodegenerative disorders and for tissue regeneration. A fresh perspective is presented on the design and characterization of nanocarriers to accelerate translation from basic research to clinical application of miRNA-nanoparticles. Main challenges in the engineering of miRNA-loaded nanoparticles are discussed, and key application examples are highlighted to underline their therapeutic potential for effective and personalized medicine.
SN  - 0168-3659
SN  - 1873-4995
ER  -

Abstract

Related

Cite